United States (US) Hereditary Angioedema Market (2025-2031) | Share, Companies, Trends, Outlook, Value, Competitive Landscape, Analysis, Industry, Growth, Segmentation, Forecast, Size & Revenue

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Hereditary Angioedema Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Hereditary Angioedema Market - Industry Life Cycle

3.4 United States (US) Hereditary Angioedema Market - Porter's Five Forces

3.5 United States (US) Hereditary Angioedema Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

3.6 United States (US) Hereditary Angioedema Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F

3.7 United States (US) Hereditary Angioedema Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing awareness about hereditary angioedema among healthcare professionals and patients

4.2.2 Advancements in diagnostic technologies leading to early detection and treatment

4.2.3 Growing research and development activities focused on developing new therapies and treatment options

4.3 Market Restraints

4.3.1 High cost associated with treatment and management of hereditary angioedema

4.3.2 Limited availability of approved therapies leading to unmet medical needs

4.3.3 Challenges in diagnosis and misdiagnosis of hereditary angioedema due to its rarity and similarity with other conditions

6.1 United States (US) Hereditary Angioedema Market, By Drug Class

6.1.1 Overview and Analysis

6.1.2 United States (US) Hereditary Angioedema Market Revenues & Volume, By Drug Class, 2021- 2031F

6.1.3 United States (US) Hereditary Angioedema Market Revenues & Volume, By C1 Esterase Inhibitor, 2021- 2031F

6.1.4 United States (US) Hereditary Angioedema Market Revenues & Volume, By Selective Bradykinin B2 Receptor Antagonist, 2021- 2031F

6.1.5 United States (US) Hereditary Angioedema Market Revenues & Volume, By Kallikrein Inhibitor, 2021- 2031F

6.1.6 United States (US) Hereditary Angioedema Market Revenues & Volume, By Others, 2021- 2031F

6.2 United States (US) Hereditary Angioedema Market, By Route of Administration

6.2.1 Overview and Analysis

6.2.2 United States (US) Hereditary Angioedema Market Revenues & Volume, By Intravenous, 2021- 2031F

6.2.3 United States (US) Hereditary Angioedema Market Revenues & Volume, By Subcutaneous Injection, 2021- 2031F

6.2.4 United States (US) Hereditary Angioedema Market Revenues & Volume, By Oral, 2021- 2031F

6.3 United States (US) Hereditary Angioedema Market, By Distribution Channel

6.3.1 Overview and Analysis

6.3.2 United States (US) Hereditary Angioedema Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F

6.3.3 United States (US) Hereditary Angioedema Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F

6.3.4 United States (US) Hereditary Angioedema Market Revenues & Volume, By Others, 2021- 2031F

7.1 United States (US) Hereditary Angioedema Market Export to Major Countries

7.2 United States (US) Hereditary Angioedema Market Imports from Major Countries

8.1 Average time from symptom onset to diagnosis

8.2 Number of clinical trials for new therapies in the pipeline

8.3 Patient adherence rate to prescribed treatment regimens

9.1 United States (US) Hereditary Angioedema Market Opportunity Assessment, By Drug Class, 2021 & 2031F

9.2 United States (US) Hereditary Angioedema Market Opportunity Assessment, By Route of Administration, 2021 & 2031F

9.3 United States (US) Hereditary Angioedema Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F

10.1 United States (US) Hereditary Angioedema Market Revenue Share, By Companies, 2024

10.2 United States (US) Hereditary Angioedema Market Competitive Benchmarking, By Operating and Technical Parameters